BioLineRx, Ltd. (BLRX)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.92+0.02 (+1.71%)
As of 9:53 AM EDT. Market open.
People also watch:
CANFAVEOBIOCACRXAPRI
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open0.95
Prev Close0.90
Bid0.91 x 200
Ask0.94 x 1000
Day's Range0.91 - 0.95
52wk Range0.71 - 1.88
1y Target EstN/A
Market Cap51.94M
P/E Ratio (ttm)-4.06
Beta0.15
Volume15,640
Avg Vol (3m)183,457
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • PR Newswireyesterday

    BioLineRx and I-Bridge Capital Establish a New Drug Development Joint Venture in China

    BioLineRx Ltd. (NASDAQ/TASE:BLRX), a clinical stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has established a joint venture (JV) with I-Bridge Capital, a Chinese venture capital fund focused on developing innovative therapies in China. The joint venture, named iPharma, will develop innovative clinical and pre-clinical therapeutic candidates originating primarily in Israel to serve the Chinese and global healthcare markets.

  • PR Newswire15 days ago

    BioLineRx Reports Second Quarter 2016 Financial Results

    TEL AVIV, Israel, Aug. 11, 2016 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic ...

  • PR Newswire15 days ago

    BioLineRx Names Philip A. Serlin as Chief Executive Officer

    TASE: BLRX), a clinical stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that Philip A. Serlin has been named Chief Executive Officer of BioLineRx, effective October 10, 2016. Mr. Serlin joined the Company in 2009 as its Chief Financial and Operating Officer.